



RPG LIFE SCIENCES LIMITED

Unit No. 208-213, B Wing, Bezzola Complex, Sion-Trombay Road, Chembur, Mumbai 400071, India
Tel: +91-22-25292152-55 ♦ Fax: +91-22-25297423

February 2, 2016

To,

The Manager Listing Department National Stock Exchange of India Limited Exchange Plaza, 5th Floor Plot No. C1, 'G' Block, Bandra-Kurla Complex Bandra (East), Mumbai 400 051.	BSE Limited Floor 25, P.J. Towers Dalal Street Mumbai 400 001.
--	---

Dear Sirs,

Sub: Unaudited financial results for the quarter ended December 31, 2015

(Scrip Code: RPGLIFE / 532983)

We submit herewith the unaudited financial results along with limited review report of the statutory auditors for the quarter ended December 31, 2015. These results have been reviewed by the Audit Committee and have been approved and taken on record by Board of Directors at their respective meetings held on February 2, 2016.

Kindly take the above on your record.

Thanking you,

Yours faithfully,
For RPG Life Sciences Limited

Rajesh Shirambekar
Head - Legal & Company Secretary



Encl: As above

RPG LIFE SCIENCES LIMITED

PART I STATEMENT OF STANDALONE UNAUDITED RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31st DECEMBER, 2015						(Rs. in lakhs)
Particulars	3 months ended 31.12.2015	3 months ended 30.09.2015	3 months ended 31.12.2014	9 months ended 31.12.2015	9 months ended 31.12.2014	Year ended 31.03.2015
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1. Income from Operations						
(a) Net Sales/Income from Operations (Net of Excise Duty)	7,202	6,720	5,648	20,572	17,189	23,308
(b) Other Operating Income	115	121	185	330	362	919
Total Income from Operations (Net)	7,317	6,841	5,833	20,902	17,551	24,227
2. Expenses						
(a) Cost of Materials Consumed	1,611	1,794	1,429	4,716	4,698	5,920
(b) Purchases of Stock-in-Trade	741	882	598	2,400	1,873	2,378
(c) Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	(74)	(432)	(90)	(216)	(218)	171
(d) Employee Benefits Expense	2,017	1,797	1,683	5,591	5,136	6,866
(e) Depreciation and Amortisation Expense	247	262	306	764	832	1,136
(f) Provision for Doubtful Debts and Advances (Net)	5	(20)	(404)	1	(386)	(323)
(g) Other Expenses	2,252	2,272	1,991	6,562	5,877	7,798
Total Expenses	6,799	6,555	5,513	19,818	17,812	23,946
3. Profit/(Loss) from Operations before Other Income, Finance Costs and Exceptional Items	518	286	320	1,084	(261)	281
4. Other Income	4	45	35	77	91	91
5. Profit/(Loss) from Ordinary Activities before Finance Costs	522	331	355	1,161	(170)	372
6. Finance Costs	55	75	88	224	200	272
7. Profit/(Loss) from Ordinary Activities before Tax	467	256	267	937	(370)	100
8. Tax Expense (including Deferred Tax)	-	-	14	-	-	-
9. Net Profit/(Loss) for the period	467	256	253	937	(370)	100
10. Paid-up Equity Share Capital (Face Value Rs. 8 each)	1,323	1,323	1,323	1,323	1,323	1,323
11. Reserves excluding Revaluation Reserves (as per last audited Balance Sheet)						11,193
12. Earnings/(Loss) per Share (of Rs. 8 each) (not annualised):						
(a) Basic	2.82	1.55	1.53	5.67	(2.24)	0.60
(b) Diluted	2.82	1.55	1.53	5.67	(2.24)	0.60

Notes:

- The above results have been reviewed by the Audit Committee and approved by the Board of Directors at its respective meetings held on 2nd February 2016.
- The results for the quarter ended 31st December, 2015 have been subjected to limited review by the statutory auditors of the Company.
- The Company is exclusively engaged in the pharmaceuticals segment.
- Figures for the prior periods have been regrouped where necessary.

For RPG Life Sciences Limited



[Signature]

CT. Renganathan
Managing Director
Mumbai, 2nd February, 2016



Regd. Off.: RPG House, 463, Dr. Annie Besant Road, Worli, Mumbai 400030, India
Tel: +91-22-24981650 / 66606375 ♦ Fax: +91-22-24970127
E-mail : info@rpglifesciences.com ♦ Web: www.rpglifesciences.com
CIN : L24232MH2007PLC169354



The Board of Directors
RPG Life Sciences Limited
RPG House
462, Dr. Annie Besant Road,
Worli, Mumbai – 400 030

1. We have reviewed the statement of unaudited financial results (the “Statement”) of RPG Life Sciences Limited (the “Company”) for the quarter ended December 31, 2015. The Statement has been prepared by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the “Listing Regulations, 2015”), which has been initialled by us for identification purposes. The Statement is the responsibility of the Company’s management and has been approved by the Board of Directors. Our responsibility is to issue a report on the Statement based on our review.
2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, “Review of Interim Financial Information Performed by the Independent Auditor of the Entity” issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement.
3. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Statement has not been prepared in all material respects in accordance with the applicable Accounting Standards prescribed under Section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounts) Rules, 2014 and other recognised accounting practices and policies, and has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Lovelock & Lewes
Firm Registration Number: 301056E
Chartered Accountants



Sumit Seth
Partner
Membership Number 105869

Mumbai
2nd February, 2016